Heart failure affects more than 6 million people in the US. The prevalence is expected to increase by more than 40% by 2030.1 More than half of patients with heart failure have some degree of SMR, which can occur due to ischemic or other cardiomyopathies.1,2 The effectiveness of MV surgery in primary MR patients is well established, but its efficacy for SMR is less well known.2 Since TEER has emerged as a treatment option, guidelines for the various clinical phenotypes of SMR are important for improving outcomes.
Hirji S, Cifu AS, Kaneko T. Interventions for Patients With Secondary Mitral Regurgitation. JAMA. 2021;325(22):2309–2310. doi:10.1001/jama.2021.2741
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: